S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival

Melissa S. DeRycke, John D. Andersen, Katherine M. Harrington, Stefan E. Pambuccian, Steve E. Kalloger, Kristin L Boylan, Peter A Argenta, Amy P Skubitz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4% S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.

Original languageEnglish (US)
Pages (from-to)846-856
Number of pages11
JournalAmerican journal of clinical pathology
Volume132
Issue number6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Endometrioid Carcinoma
Endometrial Neoplasms
Ovarian Neoplasms
Recurrence
Survival
Reverse Transcriptase Polymerase Chain Reaction
Neoplasms
Tissue Array Analysis
Cell Line
Tumor Cell Line
Western Blotting
Staining and Labeling
Messenger RNA
Genes
Proteins

Keywords

  • Endometrioid subtype
  • Gene expression
  • Ovarian cancer
  • S100A1
  • Tissue microarray

Cite this

S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival. / DeRycke, Melissa S.; Andersen, John D.; Harrington, Katherine M.; Pambuccian, Stefan E.; Kalloger, Steve E.; Boylan, Kristin L; Argenta, Peter A; Skubitz, Amy P.

In: American journal of clinical pathology, Vol. 132, No. 6, 01.12.2009, p. 846-856.

Research output: Contribution to journalArticle

DeRycke, Melissa S. ; Andersen, John D. ; Harrington, Katherine M. ; Pambuccian, Stefan E. ; Kalloger, Steve E. ; Boylan, Kristin L ; Argenta, Peter A ; Skubitz, Amy P. / S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival. In: American journal of clinical pathology. 2009 ; Vol. 132, No. 6. pp. 846-856.
@article{f16b409caa514671806bddc73ff27017,
title = "S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival",
abstract = "We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7{\%} of serous, 21.2{\%} of clear cell, 11.2{\%} of endometrioid, and 3{\%} of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4{\%} S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.",
keywords = "Endometrioid subtype, Gene expression, Ovarian cancer, S100A1, Tissue microarray",
author = "DeRycke, {Melissa S.} and Andersen, {John D.} and Harrington, {Katherine M.} and Pambuccian, {Stefan E.} and Kalloger, {Steve E.} and Boylan, {Kristin L} and Argenta, {Peter A} and Skubitz, {Amy P}",
year = "2009",
month = "12",
day = "1",
doi = "10.1309/AJCPTK87EMMIKPFS",
language = "English (US)",
volume = "132",
pages = "846--856",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival

AU - DeRycke, Melissa S.

AU - Andersen, John D.

AU - Harrington, Katherine M.

AU - Pambuccian, Stefan E.

AU - Kalloger, Steve E.

AU - Boylan, Kristin L

AU - Argenta, Peter A

AU - Skubitz, Amy P

PY - 2009/12/1

Y1 - 2009/12/1

N2 - We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4% S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.

AB - We sought to investigate the expression levels of S100A1 in ovarian cancer cell lines and tissues to correlate S100A1 with subtype, stage, grade, and relapse-free survival. S100A1 messenger RNA and protein were up-regulated in ovarian cancer cell lines and tumors compared with normal ovarian cell lines and tissues by gene microarray analysis, reverse transcriptase-polymerase chain reaction, quantitative reverse transcriptase-polymerase chain reaction, and Western immunoblotting. In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). S100A1 expression increased with increasing Silverberg grade but not stage in serous tumors. Endometrial tissue microarrays (n = 127) were 9.4% S100A1+; no correlation with stage or grade and S100A1 was found. In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer.

KW - Endometrioid subtype

KW - Gene expression

KW - Ovarian cancer

KW - S100A1

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=72949122346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949122346&partnerID=8YFLogxK

U2 - 10.1309/AJCPTK87EMMIKPFS

DO - 10.1309/AJCPTK87EMMIKPFS

M3 - Article

VL - 132

SP - 846

EP - 856

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -